IP Library › Granted Patent US 9,862,749
Granted Patent B2
US 9,862,749 · App. 15/112,118 · Granted Jan 9, 2018

Analogue peptide CMA3 derived from CM-MA peptide and use thereof

Inventor: Yoonkyung Park (Nam-myeon, KR)
Assignee: Industry-Academic Cooperation Foundation, Chosun University
C07K14/00A61K8/64A61Q19/00A61Q19/10C07K14/43563C07K14/463A61K38/00C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,862,749
App. No.
15/112,118
Granted
Jan 9, 2018
Kind
B2
Abstract

The present invention relates to a novel analogue antibiotic peptide derived from a CM-MA peptide and a use thereof. Specifically, the novel antibiotic peptides represented by SEQ. ID. NO: 2 to SEQ. ID. NO: 7 (CAM 1 to CMA 6) were synthesized by using a CM-MA antibiotic peptide, in which amphiphilic cecropin A (CA) and magainin 2 (MA) are conjugated, as a template. The synthesized antibiotic peptide exhibits antibiotic activity on gram-positive bacteria and gram-negative bacteria and low cytotoxicity on human red blood cells and human normal cell lines (HaCaT), and thus the antibiotic peptide of the present invention can be favorably used as an active ingredient of an antibiotic agent, a cosmetic composition, a food additive, a feed additive, and a biological pesticide.

Claims (18)

1. An antibiotic peptide comprising the amino acid sequence represented by SEQ. ID. NO: 1 having at least one of the following mutations of i)-v) in the sequence:

i) substitution of the 4 th amino acid residue with histidine;

ii) substitution of the 5 th amino acid residue with lysine or leucine;

iii) substitution of the 7 th amino acid residue with histidine;

iv) change in the order of the amino acid residues ranging from the 13 th residue to the 17 th residue, and substitution of one of those amino acid residues with histidine; and

v) substitution of the 15 th amino acid residue with glutamine.

2. The antibiotic peptide according to claim 1 , wherein the antibiotic peptide comprises one of the amino acid sequences represented by SEQ ID NOs: 2-7.

3. The antibiotic peptide according to claim 1 , wherein the antibiotic peptide has the antibacterial activity against gram negative or gram positive microorganism.

4. The antibiotic peptide according to claim 3 , wherein the gram negative microorganism is one or more microorganisms selected from the group consisting of Escherichia coli, Pseudomonas aeruginosa , and Salmonella typhimurium.

5. The antibiotic peptide according to claim 3 , wherein the gram positive microorganism is one or more microorganisms selected from the group consisting of Staphylococcus aureus, Listeria monocytogenes , and Staphylococcus epidermidis.

6. The antibiotic peptide according to claim 1 , wherein the antibiotic peptide exhibits low cytotoxicity to human derived cells.

7. An antibiotic agent comprising the antibiotic peptide of claim 1 as an active ingredient.

8. A cosmetic composition comprising the antibiotic peptide of claim 1 as an active ingredient.

9. A food additive comprising the antibiotic peptide of claim 1 as an active ingredient.

10. A feed additive comprising the antibiotic peptide of claim 1 as an active ingredient.

11. An antimicrobial biological pesticide comprising the antibiotic peptide of claim 1 as an active ingredient.

12. An antimicrobial quasi-drug composition comprising the antibiotic peptide of claim 1 as an active ingredient.

13. An antimicrobial method in a subject containing the step of administering an effective dose of the antibiotic peptide of claim 1 to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2016
From: PARK, YOONKYUNG
To: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
Reel/Frame 039378/0280 →
Priority Claims (1)
KR 10-2014-0005936 · Jan 17, 2014 · national
Continuity (1)
Related Publication 20160326218A1 · Nov 10, 2016